TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025

Reuters

2025/07/24

TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025

TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2553789613"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553789613\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553789613?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-24 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553789613","market":"fut","top_or_hot":-1,"title":"TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-24 22:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL2Qlcly:1","article_id":"2553789613","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553789613","pubTimestamp":1753368488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025. TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology  Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful d","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02410":"同源康医药-B"},"translate_title":"TYK Medicines Inc.宣布TY-302、TY-2699a和TY-0540的I期临床试验结果被接受在2025年ESMO大会上展示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02410":0.9},"content_text":"TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n    \n\n        TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}